Zai Lab (ZLAB) said Friday data from its ongoing phase 1 trial of zocilurtatug pelitecan showed a 53.7% intracranial objective response rate in patients with small cell lung cancer and brain metastases.

The findings, which showed that the zoci drug candidate triggers intracranial lesion regression and reduced tumor size, will be presented at the American Association for Cancer Research Annual Meeting in San Diego, according to a statement.

The potential zoci drug conjugate also demonstrated a manageable safety profile, with most adverse events reported as low grade, the company said.

The company's phase 1b/2 trial data also showcased antitumor activity in patients with extrapulmonary neuroendocrine carcinomas, with an objective response rate of 38.2%, according to the company.

Price: 24.06, Change: +0.56, Percent Change: +2.38